International Journal of Cancer最新文献

{"title":"Real-World Experience With Multimodal Treatment of Resectable Stage II-III Non-Small Cell Lung Cancer: A Single Institutional Analysis.","authors":"Raffaella Griffo, Benedikt Niedermaier, Laura V Klotz, Marc Schneider, Michael Allgäuer, Marc Kriegsmann, Romina M Roesch, Lena Brendel, Henrike Deissner, Farastuk Bozorgmehr, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin E Eichhorn, Florian Eichhorn","doi":"10.1002/ijc.70789","DOIUrl":"https://doi.org/10.1002/ijc.70789","url":null,"abstract":"<p><p>Neoadjuvant therapy has recently become an integral component of multimodal treatment for resectable lung cancer. However, real-world data on perioperative morbidity and treatment adherence remain limited. This study aimed to assess the feasibility and safety of different neoadjuvant treatment approaches applied within daily clinical routine. We retrospectively analyzed patients with resectable stage II-III non-small cell lung cancer undergoing either neoadjuvant chemoimmunotherapy or chemotherapy/chemoradiotherapy followed by curative surgical resection. Treatment groups were compared with respect to perioperative outcomes, radiologic and pathologic downstaging, and pathologic response. A total of 143 patients met the inclusion criteria, of whom 46 (32.2%) received chemoimmunotherapy and 97 (67.8%) were treated with chemotherapy prior to surgery. Adverse events leading to treatment discontinuation occurred in only two patients in the chemoimmunotherapy group and four patients in the chemotherapy group. Chemoimmunotherapy was associated with significantly higher rates of pathologic complete response (37.0% vs. 4.1%) and more pronounced nodal downstaging, with a higher proportion of patients achieving ypN0 status (76.1% vs. 34.0%). High tumoral PD-L1 expression (≥ 50%) and squamous cell carcinoma histology were independently associated with pathologic complete response. Real-world treatment with neoadjuvant chemoimmunotherapy was feasible and resulted in improved response rates compared with chemotherapy, without increasing perioperative morbidity. Histology and high PD-L1 expression may serve as predictors for complete pathologic response, although the predictive value of PD-L1 requires confirmation in larger cohorts with more complete biomarker data.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"RIST: A Potent New Combination Therapy for Glioblastoma\".","authors":"","doi":"10.1002/ijc.70777","DOIUrl":"https://doi.org/10.1002/ijc.70777","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular and Clinicopathological Characteristics Predict Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrioid Endometrial Cancer.","authors":"Tianwei Xing, Kun Wei, Yangyang He, Jiaqi Yu, Xiaohan Wu, Hongwen Gao, Ping-Li Sun","doi":"10.1002/ijc.70785","DOIUrl":"https://doi.org/10.1002/ijc.70785","url":null,"abstract":"<p><p>Rising incidence of endometrial cancer among young women has increased the demand for fertility-sparing treatment (FST) in patients with endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC). However, approximately 20%-30% of patients exhibit progesterone resistance, and reliable predictive biomarkers remain inadequately defined. Therefore, we aimed to identify biomarkers associated with treatment response and prognosis in patients undergoing FST. In this retrospective study, we analyzed 161 patients undergoing mainly progestin-based FST, including 125 with EAH and 36 with G1 EEC. Molecular classification, pretreatment pathological morphology, hormone receptor expression, oncological outcomes, recurrence, and reproductive outcomes were evaluated. According to molecular classification, the cohort included POLEmut (n = 2), NSMP (n = 143), MMRd (n = 11), and p53abn (n = 5). Over a median treatment duration of 7 months, molecular classification significantly stratified complete response (CR) rates (p = 0.027), with distinct cumulative CR curves (p = 0.034). Patients with EEC showed lower CR rates than those with EAH (p < 0.001). Reduced CR was associated with extensive lesions, larger lesion diameter, proliferative endometrial background, papillary structure, and squamous metaplasia, whereas morular metaplasia and high estrogen receptor (ER)/progesterone receptor (PR) expression predicted higher CR rates. Multivariate analysis identified MMRd and squamous metaplasia as independent predictors of recurrence. Within the NSMP subgroup, pathological morphology and PR expression further refined risk stratification. Pregnancy outcomes were comparable across molecular subtypes. These findings suggested that integrating molecular classification with clinicopathological characteristics can improve prognostic assessment and support individualized management for patients undergoing FST.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Comments on \"Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting\".","authors":"Federica Lo Prinzi, Margherita Rimini, Lorenzo Fornaro, Lorenza Rimassa, Andrea Casadei-Gardini","doi":"10.1002/ijc.70782","DOIUrl":"https://doi.org/10.1002/ijc.70782","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial Cancers Associated With Cancers of the Breast, Prostate, Colorectum, and Lung in Sweden.","authors":"Frantisek Zitricky, Kristina Sundquist, Jan Sundquist, Akseli Hemminki, Asta Försti, Kari Hemminki","doi":"10.1002/ijc.70781","DOIUrl":"https://doi.org/10.1002/ijc.70781","url":null,"abstract":"<p><p>Available epidemiological evidence shows that many cancers share familial risks, and this is increasingly confirmed by data on shared pathogenic germline gene variants between cancers. We decided to harness the world's largest resource on familial cancer to assess discordant familial risks for female breast (BC), prostate (PC), colorectal (CRC), and lung (LC) cancers with any of 22 different cancers in first-degree relatives (proband cancers). Familial relative risk was calculated as standardized incidence ratio (SIR) when either one proband or 2 or more (2+) probands were found in a family to distinguish low- and high-risk associations. Discordant familial associations of BC were significant for 12 1-proband and 5 2+ proband cancers. For PC, the numbers were 11 and 4; for CRC, they were 8 and 4; and for LC, they were 15 and 5. The results with large case numbers showed that BC, CRC, and LC associated with each other, but the familial association between PC and LC was negative. Many known or novel associations with possible genetic causes were found, including lobular BC with stomach cancer, PC with kidney cancer, CRC with squamous cell skin and thyroid cancers, and LC with gallbladder and endocrine tumors, the most common of which were parathyroid adenomas. Also, LC associations with esophageal and cervical cancers were unlikely to be due to smoking alone and require additional explanations. In conclusion, 2/3 of discordant associations could suggest low-risk genetic and environmental causation and 1/3 high-risk genetic causation, both waiting for experimental proof.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral and Fecal Microbial Dysbiosis as Non-Invasive Diagnostic Biomarkers for Gastrointestinal Cancers: A Systematic Review and Meta-Analysis of Diagnostic Accuracy.","authors":"Saidi Hu, Zhouyan Chen, Yanxia Li, Qingyan Liao, Mingdong Luo, Danyang Song, Hanyue Yu, Yuetong Gao, Shuanglong Yang, Siran Wan, Shunhong Zhang, Chenchen Luo, Lin-Yong Zhao","doi":"10.1002/ijc.70779","DOIUrl":"https://doi.org/10.1002/ijc.70779","url":null,"abstract":"<p><p>Gastrointestinal (GI) cancers, including esophageal (EC), gastric (GC), and colorectal cancer (CRC), impose a substantial global burden, with early detection remaining crucial for improving patient outcomes. The oral and gut microbiota are increasingly implicated in cancer development and hold promise as sources of non-invasive biomarkers. However, current evidence on microbiome-based diagnostics remains fragmented, and a systematic comparison of the diagnostic accuracy between oral and fecal sampling across multiple GI cancer types is lacking. To address this gap, a systematic search of PubMed, Embase, and Scopus up to December 31, 2025, identified 43 case-control studies (59 cohorts) comprising 4452 cancer patients and 5809 controls. The pooled area under the curve (AUC) was 0.846 (95% CI: 0.824-0.867), though with substantial heterogeneity (I² = 86.5%). By cancer type, pooled AUCs were 0.746 for EC (5 cohorts), 0.886 for GC (8 cohorts), and 0.850 for CRC (46 cohorts). A bivariate analysis of 20 cohorts comparing sample types found no statistically significant difference in diagnostic performance between oral (sAUC = 0.863) and fecal sampling (sAUC = 0.820; p = 0.369). While these exploratory findings suggest that oral and fecal microbial biomarkers may offer comparable diagnostic accuracy for GI cancers, with oral sampling presenting a more practical option for screening, the results are preliminary. Significant heterogeneity, a limited number of oral cohorts, and the absence of clinical control groups highlight the need for large-scale prospective studies with direct comparisons and real-world validation to validate these biomarkers for clinical translation.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Polygenic Risk Score, Sex, and Family History to Personalize the Initial Screening Age for Colorectal Cancer.","authors":"Wen Sun, Di Liu, Dongxue Wang, Jingyang Liu, Yujie Zhang, Fen Liu, Xiao Wang, Deqiang Zheng, Jianguang Ji","doi":"10.1002/ijc.70774","DOIUrl":"https://doi.org/10.1002/ijc.70774","url":null,"abstract":"<p><p>While current colorectal cancer (CRC) screening guidelines consider family history to determine starting age for screening, they inadequately incorporate other important unmodifiable risk factors, including polygenic risk score (PRS) and biological sex. In 353,118 average-risk UK Biobank participants, we used family history-stratified Cox models to estimate associations of sex and PRS with CRC incidence, metastasis, and CRC-specific mortality. We translated risk differences into risk-adapted initiation screening ages using both risk advancement period (RAP) and absolute 10-year cumulative risk. Men had a higher risk of CRC compared to women, with HRs of 1.41 (95% CI, 1.33-1.50) for those without family history and 1.42 (95% CI, 1.26-1.61) for those with family history. For each one-standard deviation (SD) increase in PRS, the risk was 1.49 times higher (95% CI, 1.45-1.53) in participants without a family history and 1.42 times higher (95% CI, 1.34-1.51) in those with a family history. The increase in PRS was associated with elevated risks of both metastatic CRC at diagnosis and CRC-specific mortality, indicating delayed diagnosis in high-PRS individuals and highlighting the potential benefit of earlier screening. Consequently, risk-adapted initiation ages ranged from before 40 years for men with a family history in the high-PRS group to after 60 years for women without a family history in the low-PRS group. Our findings demonstrate that the integration of PRS, biological sex, and family history identifies substantial heterogeneity in CRC risk and risk-adapted screening initiation ages.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on: Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.","authors":"Yu Zhang","doi":"10.1002/ijc.70778","DOIUrl":"https://doi.org/10.1002/ijc.70778","url":null,"abstract":"","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive Cervical Cancers After an HPV-Negative Test: Insights From HPV Testing Histories.","authors":"Sadaf Sakina Hassan, Sara Nordqvist Kleppe, Nijin Asinger, Jiangrong Wang, Joakim Dillner, Laila Sara Arroyo Mühr","doi":"10.1002/ijc.70783","DOIUrl":"https://doi.org/10.1002/ijc.70783","url":null,"abstract":"<p><p>Human papillomavirus (HPV) testing is the primary method for cervical screening, and a negative HPV test is associated with a very low subsequent risk of invasive cancer. Nevertheless, some cervical cancers are diagnosed following an HPV-negative test. Using Swedish registry data, we identified women diagnosed with invasive cervical cancer between 2019 and 2024 and reconstructed HPV testing histories from the National Cervical Screening Registry. The HPV test closest to diagnosis, performed before or within 30 days after diagnosis, was defined as the index test. Of 3000 women diagnosed with invasive cervical cancer, 243 (8.1%) had an HPV-negative index test. These women were older and more frequently diagnosed at advanced stages than women with an HPV-positive index test. After adjustment for age, calendar year, and histology, an HPV-negative index test remained associated with advanced-stage disease (adjusted OR 2.91, 95% CI: 2.13-4.00). Among women with an HPV-negative index test, 128 of 243 (52.7%) had no prior HPV testing recorded, 83 of 243 (34.2%) had consistently HPV-negative histories, and 32 of 243 (13.2%) had prior HPV positivity. Cytology records were available for 229 to 243 (94.2%), and 33 to 243 (13.6%) had a previous high-grade histopathological diagnosis. Among women with an HPV-negative index test, recurrent HPV positivity following an intervening negative test was observed in only one woman. Cervical cancers diagnosed after an HPV-negative test reflect heterogeneous HPV testing histories. Most women either had no prior HPV testing recorded or had consistently HPV-negative results, while HPV positivity was observed in a smaller subgroup.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Health Disparities Among Adult Cancer Survivors.","authors":"Trille K Kjaer, Anne K G Levinsen, Mia K Grand, Erik Jakobsen, Michael Borre, Robert Zachariae, Peer Christiansen, Peter Christensen, Lisbet R Hölmich, Peter de Nully Brown, Christoffer Johansen, Susanne K Kjaer, Ismail Gögenur, Lonneke van den Poll-Franse, Susanne O Dalton","doi":"10.1002/ijc.70770","DOIUrl":"https://doi.org/10.1002/ijc.70770","url":null,"abstract":"<p><p>Cancer survivors face elevated risks of age- and treatment-related health conditions, possibly due to accelerated biological aging from cancer therapy. The role of social determinants of health (SDOH) in these aging trajectories remains understudied. We conducted a retrospective cohort study of 109,224 curatively treated Danish cancer survivors (lung, breast, prostate, or colon cancer, diagnosed between 1997 and 2018) and 574,022 age- and sex-matched cancer-free individuals. SDOH was assessed using educational level and cohabitation status. Using national registries, we investigated associations between SDOH and 16 post-cancer new morbidities with Cox proportional hazard models and flexible parametric models. During a median 6.9-year follow-up, cancer survivors had significantly higher rates of new morbidities than cancer-free individuals. Lung cancer survivors had elevated hazard rates for 14 morbidities, breast cancer survivors had increased rates for 12 morbidities, prostate cancer survivors exhibited elevated rates for 8 morbidities, and colon cancer survivors had rates for 14 morbidities. Educational disparities were evident: survivors with short education had higher rates for chronic respiratory disease (HRs: 1.30-1.55 across cancer types), heart failure (HRs: 1.50-1.54 in breast and colon), diabetes (HRs: 1.67-1.95 in breast, prostate, and colon), and depression (HRs: 1.32-1.37 in breast and colon). Living alone was also associated with increased but less pronounced rates. Cancer survivors experience elevated rates for age- and treatment-related post-cancer new morbidities compared to cancer-free individuals. Sociodemographic disadvantages, particularly short education, further increase these rates. These findings suggest that SDOH play an important role in post-cancer aging, highlighting the need for targeted interventions addressing social determinants in survivorship care.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}